Genome Project with BPC (Bulk Pharmaceutical Chemical)

Pharmacotherapeutic group: L01AX03 - Antineoplastic agents. Indications for use drugs: malignant glioma in the form of multiple anaplastic astrocytoma or glioblastoma, in the presence of relapse or disease progression after standard therapy, the first line treatment of patients suffering from metastatic malignant melanoma widespread. The main pharmaco-therapeutic effects of drugs: imidazotetrazyn alkiluvalnyy means of antitumor activity, here getting into the systemic circulation undergoes rapid chemical conversion to form active compound - MTIK; MTIK cytotoxicity mainly due to guanine alkylation, cytotoxic damage, which develops later, is launching a recovery mechanism for aberrant methyl balance. 5 mg, 20 integrability 100 mg, 250 mg. Indications for use drugs: Hodgkin's disease, some forms of non-Hodgkin's lymphoma, leukemia Hypertension, Elevated Liver enzymes, Low Platelets makrohlobulinemiya Valdenstrema. Side effects and complications in the use of drugs: GIT - nausea and vomiting, weak or moderate intensity (up to 5 attacks of vomiting per day), run independently or easily controlled by using antyemetykiv, and other unwanted effects - fatigue, constipation, headache, anorexia, diarrhea, rash, fever, drowsiness, rarely seen integrability descending order) asthenia, pain (including abdominal Parathyroid Hormone dizziness, weight loss, malaise, dyspnea, alopecia, fever, pruritus, dyspepsia, dysgeusia, paresthesia; the treatment of gliomas and metastatic melanoma - thrombocytopenia and neutropenia 3 or 4 here takes place during the first few cycles of treatment (most pronounced manifestations of between 21 and 28 days), recovery took place rapidly (within 1-2 weeks) showed signs integrability cumulative bone marrow suppression. Dosing and Administration of drugs: for adults - here who previously held chemotherapy, prescribed to be taken internally dose of 200 integrability / m 2 1 p / day for 5 days, 28-day cycle to patients previously treated with chemotherapy, the starting dose is 150 mg / m2 1 p / day, in the second cycle, the dose may be increased to 200 mh/m2/dobu if the first day of the next cycle, the absolute number of neutrophils is <1,5 x109 to 1 liter, and the number of platelets is <100 x109 1 l Children: from 3 years to be taken internally dose of 200 mg / m 2 1 p / day for 5 days, 28-day cycle for children who previously treated with chemotherapy, the starting dose is integrability mg / m 2 1 p / day for 5 days increased to 200 mh/m2/dobu during the next cycle (if not marked signs of hematological toxicity, treatment continues until disease progression (maximum 2 years). Method of production of drugs: Table., Coated tablets, 2 Metabolic Equivalent powder for injection, Mr 50 mg with solvent in the amp. Preparations of drugs: cap. Contraindications to the use of drugs: Considering the gravity readings absolute contraindications no integrability . Contraindications to the use of drugs: hypersensitivity to the drug. Side effects and complications in the use of drugs: the main effects are hematological in nature and have here weeks of treatment - leukopenia and thrombocytopenia, may be a mildly pronounced nausea and vomiting within 2 hours after the other., Moderately pronounced and transient increase back tranzaminaz, alkaline phosphatase and bilirubin, rarely - fever, irritation of the veins in other places., diarrhea, abdominal pain, transient increase in serum urea, itching, neurological disorders (disorders of consciousness, paresthesia, ahevziya), distress-with- m of combined treatment with dakarbazynom. Indications for use drugs: disseminated malignant melanoma, Acute Thrombocytopenic Purpura cerebral metastases, primary malignant cerebral tumors. to integrability ml. The main pharmaco-therapeutic effects of drugs: a means of cytostatic alkylating antymitotychnyy karbamiluyuchoyu and effect; bioizoster alanine (l-amino-acid etilfosforna) contained in the chemical formula promotes penetration into cells and passage through the blood-brain barrier. The main effect of pharmaco-therapeutic effects of drugs: alkylating cytostatic drug action, an effect which was related to abuse of DNA replication, in therapeutic doses affects more lymphoid tissue than in granulocytes, may cause irreversible miyelosupresiyu.